Dr. Parven Luthra
Teva API as Head R&D India
links
https://in.linkedin.com/pub/dr-parven-luthra/15/224/1ahttps://www.facebook.com/parven.luthra
parvenluthra@gmail.com
http://www.yatedo.com/p/Dr.+Parven+Luthra/normal/aaacd827834f5f7a5470e4b85b9cfade
https://plus.google.com/115924004837605689116/about
Parven Luthra
Experience
NOW
Teva API as Head R&D India
Teva API as Head R&D India
Vice president API R&D
Actavis Pharma ( Watson Pharma pvt ltd.)
I
am heading group of about 85 scientist working in the areas of process
development, analytical development and technology transfer.
Head-API development
Sandoz Pvt. Ltd.
I was responsible for all research and development activities for developing processes for new APIs.
Vice president
Parabolic drugs Ltd.
Heading
a group of about 80 scientists working in the areas of Chemical
research , analytical research, Intellectual property management and
regulatory affairs. The major goal is to develop cost efficient, non
infringing process for various therapeutic segments. Also responsible
for the contract research and CRAMS activities also.
Associate vice president ( Chemical research development and IPR)
Alembic Ltd.
Heading the API research and development acitivites and head of IPR department at BIOARC , Alembic ltd.
Asst. General Manager
orchid chemicals and pharmaceuticals ltd.
Working as head of R&D for developing process for APIs
Education
Patents by Inventor Parven Kumar Luthra
Application number: 20150038727
Abstract: The present
invention relates to a process for preparing silodosin with high optical
purity up to 99.9% enantiomeric excess (e.e.) or above. The process
makes use of a method step, in which the enantiomers contained in a
racemic mixture of a compound represented by the general formula V:
wherein * denotes the asymmetric center, R1 is a protecting group, and
R2 is cyano or carbamoyl, are separated.
Type:
Application
Filed:
October 19, 2012
Issued:
February 5, 2015
Assignee:
SANDOZ AG
Inventors:
Parven Kumar Luthra, Sachin Bhuta,
Chandrakant Pise Abhinay, N. Chavan Dattatraya, D. Metkar Shashikant
https://www.google.co.in/patents/WO2013056842A1
The molecular structure of silodosin (XXV) is shown below.
(XXV)
Scheme 5. Conversion of com ound V to silodosin
Example 15. Silodosin (XXV)
10.0 g of crude silodosin (optical purity = 92.0% e.e.) was dissolved in isopropyl acetate (160 ml) at 55°C. The resulting clear solution was gradually cooled to 25°C under stirring. The suspension was further cooled to 15°C and stirred for 2 hours. The precipitated solid was filtered and dried at 50°C under vacuum to obtain 8.2 g of XXV with an optical purity of 98.0% e.e. Example 16. Silodosin (XXV)
10.0 g of crude silodosin (optical purity = 98.0% e.e.) was dissolved in isopropyl acetate (160 ml) at 55°C. The resulting clear solution was gradually cooled to 25°C under stirring. The suspension was further cooled to 15°C and stirred for 2 hours. The precipitated solid was filtered and dried at 50°C under vacuum to obtain 8.0 g of XXV with an optical purity of 99.5% e.e.
https://www.google.co.in/patents/WO2013056842A1
The molecular structure of silodosin (XXV) is shown below.
(XXV)
Scheme 5. Conversion of com ound V to silodosin
Example 15. Silodosin (XXV)
10.0 g of crude silodosin (optical purity = 92.0% e.e.) was dissolved in isopropyl acetate (160 ml) at 55°C. The resulting clear solution was gradually cooled to 25°C under stirring. The suspension was further cooled to 15°C and stirred for 2 hours. The precipitated solid was filtered and dried at 50°C under vacuum to obtain 8.2 g of XXV with an optical purity of 98.0% e.e. Example 16. Silodosin (XXV)
10.0 g of crude silodosin (optical purity = 98.0% e.e.) was dissolved in isopropyl acetate (160 ml) at 55°C. The resulting clear solution was gradually cooled to 25°C under stirring. The suspension was further cooled to 15°C and stirred for 2 hours. The precipitated solid was filtered and dried at 50°C under vacuum to obtain 8.0 g of XXV with an optical purity of 99.5% e.e.
Patent number: US 7968731
Abstract: An improved
process is described for the purification of ropinirole hydrochloride.
The process includes (i) dissolving ropinirole hydrochloride in water;
(ii) treating the solution obtained in step (i) with sodium dithionate
and charcoal; (iii) treating the filtrate obtained in step (ii) with
water immiscible solvent and base and isolating the free base; and (iv)
treating the free base obtained in step (iii) with ethanolic HCl to give
ropinirole hydrochloride.
Type:
Grant
Filed:
March 21, 2007
Issued:
June 28, 2011
Assignee:
Alembic Limited
Inventors:
Pandurang Balwant Deshpande, Ashok Prataprai
Shanishchara, Trushar Rajanikant Shah, Hitarth Harshendu Acharya,
Parven Kumar Luthra
The present invention relates to a process for the purification of Ropinirole hydrochloride of formula (Ia).
According to the present invention, there is provided an improved process for purification of Ropinirole hydrochloride of formula (Ia)
The present invention relates to a process for the purification of Ropinirole hydrochloride of formula (Ia).
According to the present invention, there is provided an improved process for purification of Ropinirole hydrochloride of formula (Ia)
-
- comprising steps of:
- (i) dissolving Ropinirole hydrochloride in water;
- (ii) treating the solution obtained in step (i) with sodium dithionate and charcoal;
- (iii) treating the filtrate obtained in step (ii) with water immiscible solvent and base and isolating the free base;
- (iv) treating the free base obtained in step (iii) with ethanolic HCl to give Ropinirole hydrochloride.
Patent number: 6384215
Abstract: The present
invention provides new thioester derivatives of
4-halogeno-2-methoxyimino-3-oxo-butyric acid of the general formula (I),
also, the invention provides a method by which the said thioester
derivatives can be prepared by reacting
4-halogeno-2-methoxyimino-3-oxo-butyric acid of the general formula (II)
with 2-mercapto-5-substituted-1,3,4-oxadiazoles of the general formula
(III) in a solvent, in the presence of DMF/POCl3 and in presence of an
organic base and if desired the so obtained thioester derivatives so
obtained are reacted with 7-amino-cephem carboxylic acids of the general
formula (V) to produce condensed products which are insitu reacted with
thiourea to get cephalosporin antibiotic compounds having the general
formula (VI).
Type:
Grant
Filed:
June 7, 2001
Issued:
May 7, 2002
Assignee:
Orchid Chemicals & Pharmaceuticals Ltd.
Inventors:
Pandurang Balwant Deshpande, Parven Kumar Luthra
WO2013001511
- Vice President R&D at Watson Pharmaceuticals
/////////////Parven Luthra
No comments:
Post a Comment